You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 4,233,285

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,233,285

Title:	Mercaptocarboxylic acid radiopharmaceuticals
Abstract:	Mercaptocarboxylic acid chelated heavy metal radioisotope pharmaceuticals and methods for making them.
Inventor(s):	Winchell; Harry S. (Lafayette, CA), Lin; Tz-Hong (Berkeley, CA)
Assignee:	Medi-Physics, Inc. (Emeryville, CA)
Application Number:	05/359,719
Patent Claims:	1. A radiopharmaceutical comprising a complex of a mercaptocarboxylic acid chelating agent having at least one carboxylic acid group and at least one mercapto group with a radioactive heavy metal ion produced by reduction with stannous chloride in the presence of the chelating agent wherein said complex is formed at a pH of from about 2 to 4 and the mole ratio of said metal chelating agent to stannous chloride present to reduce such metal ion is about three to one. 2. The radiopharmaceutical of claim 1 wherein said chelating agent is selected from the group consisting of mercaptoacetic acid, 2-mercaptopropionic acid, 3-mercaptopropionic acid, mercaptosuccinic acid and 2,3-dimercaptosuccinic acid. 3. The radiopharmaceutical of claim 2 wherein said agent is 2,3-dimercaptosuccinic acid and said heavy metal ion is technetium 99m. 4. A reagent for producing a radiopharmaceutical comprising an aqueous solution containing mercaptocarboxylic acid chelating agent having at least one carboxylic acid group and at least mercapto group, 99-m-technetium pertechnetate and stannous chloride, where the mole ratio of said chelating agent to stannous chloride is about 3 to 1 and the pH of said solution being from about 2 to about 4. 5. The composition of claim 4 wherein said chelating agent is selected from the group consisting of mercaptoacetic acid, 2-mercaptopropionic acid, 3-mercaptopropionic acid, mercaptosuccinic acid and 2,3-dimercaptosuccinic acid. 6. The composition of claim 4 wherein said agent is 2,3-dimercaptosuccinic acid. 7. A method of imaging the renal cortex, brain abnormalities, tumors and myocardial infarcts of a patient comprising intravenously injecting said patient with a radiopharmaceutical comprising a complex of a mercaptocarboxylic acid metal chelating agent with a radioactive heavy metal ion produced by reduction with stannous chloride, wherein said complex is formed at a pH of from 2 to 4 and the mol ratio of said metal chelating agent to stannous chloride present to produce metal ion is about three to one, and scanning with a suitable apparatus. 8. The method of claim 7 wherein said chelating agent is selected from the group consisting of mercaptoacetic acid, 2-mercaptopropionic acid, 3-mercaptopropionic acid, mercaptosuccinic acid and 2,3-dimercaptosuccinic acid. 9. The method of claim 8 wherein said metal ion is technetium-99m and said chelating agent is 2,3-dimercaptosuccinic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.